The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

Facing Ebola outbreak, Uganda approves 3 experimental treatments

| | June 25, 2019

Health authorities in Uganda have approved the use of three experimental treatments against Ebola in the country. The decision comes in anticipation of spillover from an ongoing outbreak in neighboring Democratic Republic of Congo and after the deaths of two people in Uganda last week who had traveled across the border from DRC with the virus.

Reuters reports that the treatments, all of which are already being used DRC, will be shipped to Uganda so that health workers can respond to any further infections.

The drugs include the antibodies ZMapp (made by Mapp Biopharmaceuticals) and REGN-EB3 (made by Regeneron Pharmaceuticals), as well as Gilead Sciences’s antiviral Remdesivir, which was recently shown to work by disrupting viral genome synthesis.

All of the treatments have been in use in DRC since last fall. Protocols for a fourth treatment are underway, World Health Organization (WHO) spokesman Tarik Jasarevic wrote in an email to Reuters.

The latest outbreak of Ebola began last August and has so far killed more than 1,400 people in DRC, making it the second worst outbreak of the virus after the West African outbreak that killed more than 11,000 people between 2014 and 2016.

Read full, original post: Experimental Ebola Treatments Approved for Use in Uganda

Related article:  Are we fighting diseases wrong? Researcher suggests a better approach is building tolerance to infection
The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend